Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Impact Of Vitamin D Level Pre and Post Allogeneic Hematopoietic Stem Cell Transplant

Kristen Beebe, PA-C, Jane Olsen, NP, Yu-hui Chang, PhD, Mary Burkhart, NP, Lori DeCook, PA-C, Susan Gerber, PA-C, Kimberley Settineri, PA-C, Jane Palmer, NP, Joanne Schlesinger, NP, Roberta Adams, MD, Veena Fauble, MD, Nandita Khera, MD, MPH, Jared Klein, MD, Jose Leis, MD, PhD, Pierre Noel, MD, Meagan Higgins, NP, Craig Reeder, MD, James L Slack, MD, Lisa Sproat, MD, MSW

Blood (2013) 122 (21): 4616.

https://doi.org/10.1182/blood.V122.21.4616.4616

Published: 2013

Journal Articles

Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes

Sameer A. Parikh, MD, Tait D Shanafelt, MD, Kari G. Rabe, MS, Wei Ding, MD, PhD, Timothy G. Call, MD, Susan Schwager, Diane F. Jelinek, PhD, Neil E. Kay, MD, Susan L Slager, PhD, Jose Leis, MD, PhD

Blood (2013) 122 (21): 4178.

https://doi.org/10.1182/blood.V122.21.4178.4178

Published: 2013

Journal Articles

Patterns of Acute and Chronic Graft-Versus-Host Disease Following ATG-Based Conditioning for Allogeneic Hematopoietic Cell Transplantation

Nandita Khera, MD, Amylou C. Dueck, PhD, Veena Devi Salem Fauble, MD, Lisa Sproat, MD, MSW, Pierre Noel, MD, Jose Leis, MD, PhD, Roberta H. Adams, MD, James L Slack, MD

Blood (2012) 120 (21): 4479.

https://doi.org/10.1182/blood.V120.21.4479.4479

Published: 2012

Journal Articles

Impact of Vitamin D Level After Allogeneic Hematopoietic Stem Cell Transplant

Lisa Sproat, MD, MSW, Jane Olsen, NP, Kristen Beebe, PA-C, Rochelle Chiffelle, DNP, Susan Gerber, PA-C, Brooke Loewen, PA-C, Jane Palmer, NP, Angela Toro, NP, Roberta Adams, MD, Veena Devi Salem Fauble, MD, Nandita Khera, MD, Jose Leis, MD, PhD, Craig Reeder, MD, James L Slack, MD, Pierre Noel, MD

Blood (2012) 120 (21): 1954.

https://doi.org/10.1182/blood.V120.21.1954.1954

Published: 2012

Journal Articles

Allosteric Akt Inhibitor MK2206 Synergizes with Bendamustine in Promoting the Apoptosis of Chronic Lymphocytic Leukemia Cells and Selectively Targets B-Cell Receptor Mediated Cytokine Production

Wei Ding, MD, PhD, Tait D. Shanafelt, MD, Connie Lesnick, M.Sc, Traci Sassoon, Charla Secreto, Charles Erlichman, MD, Jose Leis, MD, PhD, Timothy G. Call, MD, Deborah Bowen, CNP, Shaji K. Kumar, MD, Neil E. Kay, MD

Blood (2012) 120 (21): 3928.

https://doi.org/10.1182/blood.V120.21.3928.3928

Published: 2012

Journal Articles

LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.

Craig Reeder, MD, Stephen M Ansell, M.D., Ph.D., Katherine Gano, Amylou C. Dueck, PhD, Christopher Conley, MD, Grzegorz S. Nowakowski, Kelly Curtis, MD, John Camoriano, MD, Jose Leis, MD, PhD, James L Slack, MD, Riccardo Valdez, MD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Keith Stewart, MD, Thomas E. Witzig, MD

Blood (2012) 120 (21): 2741.

https://doi.org/10.1182/blood.V120.21.2741.2741

Published: 2012

Journal Articles

Allogeniec Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.

Veena Devi Salem Fauble, MD, James L Slack, MD, William Hogan, MD, Vivek Roy, M.D., Jose Leis, MD, PhD, Amylou C. Dueck, PhD, Mark R Litzow, MD, Mrinal M. Patnaik, MBBS, MD, Pardanani Animesh, MBBS, PhD, Candido E. Rivera, MD, Raoul Tibes, MD, PhD, John Camoriano, MD, Roberta H. Adams, MD, Pierre Noel, MD, Nandita Khera, MD, Lisa Sproat, MD, MSW, Ruben A. Mesa

Blood (2012) 120 (21): 2850.

https://doi.org/10.1182/blood.V120.21.2850.2850

Published: 2012

Journal Articles

Survival of Patients with Clinically Identified Monoclonal B-Cell Lymphocytosis (MBL) Relative to the Age and Sex Matched General Population

Tait Shanafelt, MD, Neil E. Kay, Kari Rabe, Timothy Call, MD, Clive S. Zent, MD, Susan Schwager, Jose Leis, Diane F. Jelinek, PhD, Susan Slager, PhD, Curtis Hanson

Blood (2010) 116 (21): 700.

https://doi.org/10.1182/blood.V116.21.700.700

Published: 2010

Journal Articles

Lendalidomide Consolidation After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL

Tait Shanafelt, MD, Han Tun, MD, Curtis Hanson, Clive S. Zent, MD, Jose Leis, Timothy Call, MD, Betsy LaPlant, Deborah Bowen, Kristina Laumann, Diane F. Jelinek, PhD, Neil E. Kay

Blood (2010) 116 (21): 1379.

https://doi.org/10.1182/blood.V116.21.1379.1379

Published: 2010

Journal Articles

Infectious Complications In a Prospective Cohort of Community Based Newly Diagnosed Patients with Chronic Lymphocytic Leukemia (CLL).

Jonathan Moreira, MD, Timothy Call, MD, Kari Rabe, Randy Wendt, Clive S. Zent, MD, Neil E. Kay, MD, Deborah Bowen, Jose Leis, MD, Susan Slager, PhD, Jon Wilson, MD, Tait Shanafelt, MD

Blood (2010) 116 (21): 4610.

https://doi.org/10.1182/blood.V116.21.4610.4610

Published: 2010

Journal Articles

Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci

Blood (2010) 116 (21): 2443.

https://doi.org/10.1182/blood.V116.21.2443.2443

Published: 2010

Journal Articles

A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity.

Craig B. Reeder, MD, Donna E. Reece, Vishal Kukreti, MD, FRCPC, Joseph R. Mikhael, MD, Christine Chen, MD, Suzanne Trudel, MD, Kristina Laumann, Joseph Hentz, Nick Pirooz, Jg Piza, MD, Victor J Jimenez Zepeda, Rafael Fonseca, P. Leif Bergsagel, Jose Leis, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, A. Keith Stewart, MBChB

Blood (2009) 114 (22): 616.

https://doi.org/10.1182/blood.V114.22.616.616

Published: 2009

Journal Articles

Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology.

Mark C Lanasa, MD, PhD, Sallie D Allgood, MS, Susan L Slager, PhD, Nicola J Camp, PhD, Neil E. Kay, MD, Logan G Spector, PhD, Laura Z. Rassenti, PhD, Curtis A. Hanson, MD, Jon P Gockerman, MD, Barbara K Goodman, PhD, Sara S Strom, PhD, Timothy G Call, MD, James R Cerhan, MD, PhD, Jose Leis, MD, Gerald Marti, MD, PhD, Lynn Goldin, PhD, J. Brice Weinberg, Neil E Caporaso, MD

Blood (2009) 114 (22): 1241.

https://doi.org/10.1182/blood.V114.22.1241.1241

Published: 2009

Journal Articles

Recurrent Chromosome Abnormalities Define Non-Overlapping, Unique Subgroups of Tumors in Chronic Lymphocytic Leukemia Patients with Known Karyotypic Abnormalities

Victor H Jimenez-Zepeda, Wee Joo Chng, Esteban Braggio, Neil Kay, Jose Leis, Rafael Fonseca

Blood (2008) 112 (11): 4176.

https://doi.org/10.1182/blood.V112.11.4176.4176

Published: 2008

Journal Articles

Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Mohamed L. Sorror, Barry Storer, Brenda M. Sandmaier, Michael B. Maris, Judith Shizuru, Jose Leis, Edward Agura, Thomas Chauncey, Michael Pulsipher, Peter McSweeney, James Wade, Benedetto Bruno, Amelia Langston, Jerry Radich, Dietger Niederwieser, Karl Blume, Rainer Storb, David G. Maloney

Blood (2007) 110 (11): 1662.

https://doi.org/10.1182/blood.V110.11.1662.1662

Published: 2007

Journal Articles

Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.

Christoph Kahl, MD, Barry Storer, PhD, Marco Mielcarek, MD, Mike Maris, MD, Brenda Sandmaier, MD, David Maloney, MD, PhD, Thomas Chauncey, MD, Dietger Niederwieser, MD, Peter McSweeney, MD, Benedetto Bruno, MD, Karl Blume, MD, James Wade, MD, Jose Leis, MD, PhD, Emilia Langston, MD, Michael Pulsipher, MD, Edward Agura, MD, Rainer Storb, MD

Blood (2005) 106 (11): 703.

https://doi.org/10.1182/blood.V106.11.703.703

Published: 2005

Journal Articles

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

Mohamed Sorror, MD, MSc, Michael Maris, MD, Barry Storer, PhD, Brenda Sandmaier, MD, Monic Stuart, MD, Ute Hegenbart, MD, Edward Agura, MD, Thomas Chauncey, MD, Jose Leis, MD, PhD, Michael Pulsipher, MD, Peter McSweeney, MD, Jerry Radich, MD, James Wade, MD, Benedetto Bruno, MD, Amelia Langston, MD, Dietger Niederwieser, MD, Karl Blume, MD, Rainer Storb, MD, David Maloney, MD, PhD

Blood (2004) 104 (11): 2323.

https://doi.org/10.1182/blood.V104.11.2323.2323

Published: 2004

NARROW

Impact Of Vitamin D Level Pre and Post Allogeneic Hematopoietic Stem Cell Transplant

Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes

Patterns of Acute and Chronic Graft-Versus-Host Disease Following ATG-Based Conditioning for Allogeneic Hematopoietic Cell Transplantation

Impact of Vitamin D Level After Allogeneic Hematopoietic Stem Cell Transplant

Allosteric Akt Inhibitor MK2206 Synergizes with Bendamustine in Promoting the Apoptosis of Chronic Lymphocytic Leukemia Cells and Selectively Targets B-Cell Receptor Mediated Cytokine Production

LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.

Allogeniec Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.

Survival of Patients with Clinically Identified Monoclonal B-Cell Lymphocytosis (MBL) Relative to the Age and Sex Matched General Population

Lendalidomide Consolidation After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL

Infectious Complications In a Prospective Cohort of Community Based Newly Diagnosed Patients with Chronic Lymphocytic Leukemia (CLL).

Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci

A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity.

Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology.

Recurrent Chromosome Abnormalities Define Non-Overlapping, Unique Subgroups of Tumors in Chronic Lymphocytic Leukemia Patients with Known Karyotypic Abnormalities

Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only